Arax Advisory Partners’s Kyntra Bio KYNB Stock Holding History

Arax Advisory Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-147	Closed	-$1.47K	–	2526
2024 Q3	$1.47K	Hold	147	–	–	﹤0.01%	2141
2024 Q2	$3.29K	Buy	+147	New	+$4.54K	﹤0.01%	1788

Other funds holding KYNB

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Arax Advisory Partners's KYNB Position: Q4 2024 in Review

Arax Advisory Partners sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 147 shares — an estimated $1.47K sold.

Arax Advisory Partners first reported a position in KYNB in Q2 2024 and held it in 2 quarters. The position peaked at $3.29K in Q2 2024. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

Arax Advisory Partners reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
Arax Advisory Partners sold 147 Kyntra Bio shares in Q4 2024, an estimated $1.47K.
Arax Advisory Partners first reported a position in Kyntra Bio in Q2 2024 and held it in 2 quarters.
Arax Advisory Partners's Kyntra Bio position peaked at $3.29K in Q2 2024.
68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.